Meeting
2020 ASCO Virtual Scientific Program
Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.
Authors
Bryan Haugen
University of Colorado, Aurora, CO
Bryan Haugen , Jena French , Francis P. Worden , Bhavana Konda , Eric Jeffrey Sherman , Ramona Dadu , Andrew G. Gianoukakis , Eric G. Wolfe , Nathan R. Foster , Daniel W. Bowles , Lori J. Wirth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT02973997
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6512)
DOI
10.1200/JCO.2020.38.15_suppl.6512
Abstract #
6512
Poster Bd #
173
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.
First Author: Carlos Rojas
Poster
2023 ASCO Annual Meeting
A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer.
First Author: Amr Hesham Abdelhamid Ahmed
Poster
2023 ASCO Annual Meeting
PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.
First Author: Manuel Rodrigues
Poster
2019 ASCO Annual Meeting
Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study.
First Author: Martin Gutierrez